KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis

To evaluate the efficacy of subcutaneous (SC) KPL-716 in reducing pruritis in subjects with moderate to severe PN experiencing severe itching.

Kiniska Pharmaceuticals, Ltd.
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Request Information
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.